Author

Wally Rapattoni

Observed names: W Rapattoni, WALLY RAPATTONI

Observed institution: Janssen Canada (Canada)

ORCID: 0000-0001-6400-982X

Observed ORCID: 0000-0001-6400-982X

OpenAlex ID: A5015240656

Impact of Canagliflozin on Kidney and Cardiovascular Outcomes by Type 2 Diabetes Duration: A Pooled Analysis of the CANVAS Program and CREDENCE Trials

2024 · Sheldon W. Tobe, Thomas A. Mavrakanas, et al. · Diabetes Care · 15

PDF

CANadian CAnagliflozin REgistry: Effectiveness and safety of canagliflozin in the treatment of type 2 diabetes mellitus in Canadian clinical practice

2018 · Vincent Woo, Alan Bell, et al. · Diabetes Obesity and Metabolism · 10

PDF

Primary and Secondary Cardiovascular and Kidney Prevention With Canagliflozin: Insights From the CANVAS Program and CREDENCE Trial

2024 · Abhinav Sharma, Amir Razaghizad, et al. · Journal of the American Heart Association · 8

PDF

Kidney protection with canagliflozin: A combined analysis of the randomized CANVAS program and CREDENCE trials

2023 · Vikas S. Sridhar, Brendon L. Neuen, et al. · Diabetes Obesity and Metabolism · 8

PDF

Effects of canagliflozin on cardiovascular and kidney events in patients with chronic kidney disease with and without peripheral arterial disease: Integrated analysis from the CANVAS Program and CREDENCE trial

2023 · Tae Won Yi, Michelle M.Y. Wong, et al. · Diabetes Obesity and Metabolism · 7

PDF

A retrospective observational population‐based study to assess the prevalence and burden of illness of type 2 diabetes with an estimated glomerular filtration rate < 90 mL/min/1.73 m 2 in Ontario, Canada

2020 · Wally Rapattoni, David Zante, et al. · Diabetes Obesity and Metabolism · 5

PDF

Cardiovascular and kidney outcomes with canagliflozin according to type 2 diabetes treatment targets at baseline: Data from the CANVAS programme and CREDENCE

2023 · Michael A. Tsoukas, Vincent Woo, et al. · Diabetes Obesity and Metabolism · 2

PDF

Effects of canagliflozin on cardiovascular and kidney outcomes and mortality in primary and secondary cardiovascular prevention: pooled analysis from the CANVAS program and CREDENCE trial

2022 · F Ang, W Rapattoni, et al. · European Heart Journal · 2

Timing of statistical benefit of canagliflozin in patients with type 2 diabetes for cardiovascular and heart failure outcomes: Insights from the CANVAS Program and CREDENCE trial

2023 · Abhinav Sharma, Pedro Marques, et al. · Diabetes Obesity and Metabolism · 1

PDF

Author response for "Timing of statistical benefit of canagliflozin in patients with type 2 diabetes for cardiovascular and heart failure outcomes: Insights from the CANVAS Program and CREDENCE trial"

2023 · Abhinav Sharma, Pedro Marques, et al. · Publons reviews and discussion

Effects of Canagliflozin (CANA) on Cardiovascular (CV), Kidney, and Albuminuria Outcomes by Diabetes Duration: Pooled Analysis From the CANVAS Program and CREDENCE

2022 · Sheldon W. Tobe, Harpreet S. Bajaj, et al. · Journal of the American Society of Nephrology

856-P: Cardiovascular (CV) and Kidney Outcomes with Canagliflozin (CANA) According to Type 2 Diabetes (T2D) Treatment Targets at Baseline (BL) : Data from the CANVAS Program and CREDENCE

2022 · VINCENT C. WOO, MICHAEL TSOUKAS, et al. · Diabetes

FC 122: Effects of Canagliflozin on Cardiovascular and Kidney Events in Patients With Chronic Kidney Disease With and Without Peripheral Vascular Disease: Integrated Analysis From the Canvas Program and Credence Trial

2022 · Adeera Levin, Paul Poirier, et al. · Nephrology Dialysis Transplantation

PDF

P0775a Retrospective Observational Cohort Study to Assess the Prevalence of Chronic Kidney Disease Among Type 2 Diabetes Mellitus Patients in Ontario, Canada

2020 · Wally Rapattoni, David Zante, et al. · Nephrology Dialysis Transplantation

Canadian Canagliflozin Registry: Prospective, Observational Assessment of Canagliflozin Treatment in Type 2 Diabetes Mellitus; 12 Month Results

2018 · Maureen Clement, Alan Bell, et al. · Canadian Journal of Diabetes

Canadian Canagliflozin Registry: A Prospective, 12-Month Observational Study of Canagliflozin Treatment in Type 2 Diabetes Mellitus: Achievement of the Triple Composite Endpoint and Low Incidence of Severe Hypoglycemia

2018 · Harpreet Bajaj, Maureen Clement, et al. · Canadian Journal of Diabetes

CANadian CAnagliflozin REgistry (CanCARE)—A Prospective, Observational Assessment of Canagliflozin (CANA) Treatment in Type 2 Diabetes Mellitus (T2DM)—Twelve-Month Results

2018 · VINCENT C. WOO, ALAN D. BELL, et al. · Diabetes

Works count: 17

Citation count: 58

H-index: 5

I10-index: 2